Roth GA, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.

Article  PubMed  PubMed Central  Google Scholar 

Mensah GA, et al. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol. 2023;82(25):2350–473.

Article  PubMed  PubMed Central  Google Scholar 

Timmis A, et al. European Society of Cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41(1):12–85.

Article  PubMed  Google Scholar 

GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440):2100–2132.

Barbato E, et al. Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project. Eur Heart J. 2020;41(27):2579–88.

Article  PubMed  Google Scholar 

Ference BA et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472.

Banach M, Surma S. A look to the past—what has had the biggest impact on lipids in the last four decades? A personal perspective. Arch Med Sci. 2023;19(3):559–64. https://doi.org/10.5114/aoms/166256.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Banach M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis. 2023;79:2–11.

Article  PubMed  Google Scholar 

Ray KK, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12(1):19–28.

Article  PubMed  CAS  Google Scholar 

Henney NC, Banach M, Penson PE. RNA silencing in the management of dyslipidemias. Curr Atheroscler Rep. 2021;23(11):69. https://doi.org/10.1007/s11883-021-00968-7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Surma S, Shapiro MD, Banach M. Breaking new ground in lipid management: Insights from the 2024 American College of Cardiology Scientific Sessions. Pharmacol Res. 2024;205: 107246.

Article  PubMed  Google Scholar 

Robinson JG, et al. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. J Clin Lipidol. 2019; 13(4):525–537.

Boren J, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313–30.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ning H, Perak AM, Siddique J, Wilkins JT, Lloyd-Jones DM, Allen NB. Association between life’s essential 8 cardiovascular health metrics with cardiovascular events in the cardiovascular disease lifetime risk pooling project. Circ Cardiovasc Qual Outcomes. 2024;19: e010568. https://doi.org/10.1161/CIRCOUTCOMES.123.010568.

Article  Google Scholar 

Serban MC, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386–95.

Article  PubMed  CAS  Google Scholar 

Banach M, Penson PE. Adherence to statin therapy: it seems we know everything, yet we do nothing. Eur Heart J Open. 2022;2(6):oeac071. https://doi.org/10.1093/ehjopen/oeac071.

Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrières J, Laufs U, Mostaza JM, Nanchen D, Rietzschel E, Strandberg T, Toplak H, Visseren FLJ, Catapano AL; SANTORINI Study Investigators. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023; 29:100624. https://doi.org/10.1016/j.lanepe.2023.100624.

Schubert J, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2021;42(3):243–52.

Article  PubMed  CAS  Google Scholar 

Lee SJ, Joo JH, Park S, Kim C, Choi DW, Hong SJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Nam CM, Hong MK. Combination lipid-lowering therapy in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2023;82(5):401–10. https://doi.org/10.1016/j.jacc.2023.05.042.

Article  PubMed  Google Scholar 

Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38):3720–3826.

Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.

Article  PubMed  Google Scholar 

Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.

Article  PubMed  Google Scholar 

Dyrbus K, et al. Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry. Atherosclerosis. 2021;333:16–23.

Article  PubMed  CAS  Google Scholar 

Banach M, et al. Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021;166: 105499.

Article  PubMed  CAS  Google Scholar 

Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokgözoğlu LS, Connolly DL, Gerrits AJ, Stroes ESG, Masana L, Kastelein JJP. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830–3.

Article  PubMed  CAS  Google Scholar 

Penson PE, et al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle. 2022;13(3):1596–622.

Article  PubMed  PubMed Central  Google Scholar 

Paponja K, Pećin I, Reiner Ž, Banach M. Bempedoic acid: new evidence and recommendations on use. Curr Opin Lipidol. 2024;35(1):41–50.

PubMed  CAS  Google Scholar 

Banach M, et al. Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach. Cardiovasc Diabetol. 2022;21(1):263.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Banach M, Surma S, Kapłon-Cieślicka A, Mitkowski P, Dzida G, Tomasik T, et al. Position paper of the Polish expert group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association. Lekarz POZ. 2023;9(6):309–26.

Google Scholar 

Sosnowska B, Stepinska J, Mitkowski P, Bielecka-Dabrowa A, Bobrowska B, Budzianowski J, Burchardt P, Chlebus K, Dobrowolski P, Gasior M, Jankowski P, Kubica J, Mickiewicz A, Mysliwiec M, Osadnik T, Prejbisz A, Rajtar-Salwa R, Wita K, Witkowski A, Gil R, Banach M. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci. 2024;20(1):8–27.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lewek J, Niedziela J, Desperak P, Dyrbuś K, Osadnik T, Jankowski P, Witkowski A, Bielecka-Dąbrowa A, Dudek D, Gierlotka M, Gąsior M, Banach M. Intensive statin therapy versus upfront combination therapy of statin and ezetimibe in patients with acute coronary syndrome: a propensity score matching analysis based on the PL-ACS data. J Am Heart Assoc. 2023;12(18): e030414.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Banach M, Reiner Z, Cicero AFG, Sabouret P, Viigimaa M, Sahebkar A, Postadzhiyan A, Gaita D, Pella D, Penson PE. 2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy. Arch Med Sci. 2022;18(6):1429–34.

PubMed  PubMed Central  Google Scholar 

Ray KK, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–89.

Article  PubMed  Google Scholar 

Vrablik M, Seifert B, Parkhomenko A, Banach M, Jóźwiak JJ, Kiss RG, Gaita D, Rašlová K, Zachlederova M, Bray S, Ray KK. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis. 2021;334:66–75.

Lin I, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm. 2016;22(6):685–98.

PubMed  Google Scholar 

Nowowiejska-Wiewióra A, Wita K, Mędrala Z, Tomkiewicz-Pająk L, Bujak K, Mizia-Stec K, Brzychczy P, Gąsior M, Gąsior Z, Kulbat A, Kalarus Z, Wojakowski W, Trzeciak P, Witkowski A, Banach M, Legutko J. Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program. Kardiol Pol. 2023;81(4):359–65.

Article  PubMed  Google Scholar